Thrive Wealth Management LLC Has $2.80 Million Holdings in Johnson & Johnson (NYSE:JNJ)

Thrive Wealth Management LLC lifted its holdings in Johnson & Johnson (NYSE:JNJGet Rating) by 5.1% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,769 shares of the company’s stock after acquiring an additional 764 shares during the quarter. Johnson & Johnson makes up approximately 0.8% of Thrive Wealth Management LLC’s holdings, making the stock its 20th largest holding. Thrive Wealth Management LLC’s holdings in Johnson & Johnson were worth $2,795,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Family CFO Inc acquired a new position in Johnson & Johnson during the 4th quarter worth $26,000. Steward Financial Group LLC acquired a new position in Johnson & Johnson during the 4th quarter worth $34,000. Joseph P. Lucia & Associates LLC acquired a new position in Johnson & Johnson during the 1st quarter worth $38,000. Advocacy Wealth Management Services LLC lifted its holdings in Johnson & Johnson by 41.4% during the 1st quarter. Advocacy Wealth Management Services LLC now owns 229 shares of the company’s stock worth $41,000 after buying an additional 67 shares in the last quarter. Finally, Gibson Wealth Advisors LLC acquired a new position in Johnson & Johnson during the 4th quarter worth $49,000. Institutional investors and hedge funds own 68.78% of the company’s stock.

Insiders Place Their Bets

In other Johnson & Johnson news, CAO Robert J. Decker sold 8,462 shares of the stock in a transaction dated Thursday, May 26th. The stock was sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the completion of the transaction, the chief accounting officer now owns 15,473 shares in the company, valued at approximately $2,785,140. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other Johnson & Johnson news, CAO Robert J. Decker sold 8,462 shares of the stock in a transaction dated Thursday, May 26th. The stock was sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the completion of the transaction, the chief accounting officer now owns 15,473 shares in the company, valued at approximately $2,785,140. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Kathryn E. Wengel sold 40,000 shares of the stock in a transaction dated Friday, June 10th. The stock was sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the transaction, the executive vice president now owns 71,311 shares of the company’s stock, valued at $12,336,803. The disclosure for this sale can be found here. Corporate insiders own 0.35% of the company’s stock.

Johnson & Johnson Price Performance

JNJ opened at $173.20 on Thursday. The company has a quick ratio of 1.14, a current ratio of 1.39 and a debt-to-equity ratio of 0.39. Johnson & Johnson has a 12 month low of $155.72 and a 12 month high of $186.69. The company has a fifty day simple moving average of $175.99 and a 200 day simple moving average of $174.36. The stock has a market cap of $455.76 billion, a P/E ratio of 25.21, a P/E/G ratio of 3.28 and a beta of 0.63.

Johnson & Johnson (NYSE:JNJGet Rating) last released its quarterly earnings data on Tuesday, July 19th. The company reported $2.59 EPS for the quarter, beating analysts’ consensus estimates of $2.57 by $0.02. Johnson & Johnson had a net margin of 19.21% and a return on equity of 36.56%. The business had revenue of $24.02 billion during the quarter, compared to analysts’ expectations of $23.85 billion. During the same quarter in the prior year, the company earned $2.48 EPS. The firm’s quarterly revenue was up 3.0% on a year-over-year basis. On average, research analysts expect that Johnson & Johnson will post 10.05 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 6th. Shareholders of record on Tuesday, August 23rd will be issued a dividend of $1.13 per share. This represents a $4.52 dividend on an annualized basis and a yield of 2.61%. The ex-dividend date is Monday, August 22nd. Johnson & Johnson’s dividend payout ratio (DPR) is presently 65.79%.

Wall Street Analyst Weigh In

Several research analysts have issued reports on JNJ shares. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday, May 17th. Wells Fargo & Company upped their target price on shares of Johnson & Johnson from $190.00 to $195.00 and gave the company an “overweight” rating in a research report on Wednesday, July 13th. The Goldman Sachs Group upped their target price on shares of Johnson & Johnson from $163.00 to $181.00 and gave the company a “neutral” rating in a research report on Tuesday, April 12th. Credit Suisse Group upped their target price on shares of Johnson & Johnson from $200.00 to $205.00 and gave the company an “outperform” rating in a research report on Wednesday, April 20th. Finally, Citigroup dropped their target price on shares of Johnson & Johnson from $205.00 to $201.00 in a research report on Wednesday, July 20th. Four equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $189.89.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Articles

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.